Monitor Q4 2026 for first product revenue recognition and prescription trends; the sNDA for the PIK3CA mutant label expansion is a key catalyst; watch for global regulatory submissions later this year or early next year.
Drug in focus
CELC drug pipeline →REVTORPYK
◆ Mixed Named in this 8-K- Impact
- Phase
- Approved
- Time to market
- Already approved and commercially available in the US since September 30, 2026. A supplemental NDA (sNDA) for the PIK3CA mutant indication was submitted August 26, 2026; no PDUFA goal date has been publicly confirmed yet.
- Next catalyst
- None dated
What to watchWatch for the FDA's acceptance and PDUFA goal date for the sNDA covering the PIK3CA mutant indication, which would be the next major regulatory catalyst. Also monitor Q4 2026 earnings (expected early 2027) for the first meaningful product revenue figures and prescription trends. The stock's 126.5% implied upside to the mean analyst target reflects high expectations for commercial execution, so any launch stumbles could pressure the stock further.
Price Chart
Executive Summary
Celcuity reported Q3 2026 results with no product revenue as REVTORPYK shipments began on Sept 30 and revenue is recognized upon delivery. Net loss widened to $73.3M from $43.8M a year ago, driven by $25.3M in commercial launch costs. The company highlighted strong early launch metrics: 78% of top strategic accounts have ordered, 91% of covered lives have access, and an sNDA for the PIK3CA mutant cohort was submitted.
Key Financial Metrics
Key Facts
- REVTORPYK (gedatolisib) became commercially available on Sept 30, 2026 for HR+/HER2- PIK3CA wild-type advanced breast cancer
- No product revenue recognized in Q3 2026 because shipments occurred on Sept 30 and revenue is recognized upon delivery
- Net loss Q3 2026: $73.3M ($1.33/share) vs $43.8M ($0.92/share) in Q3 2025
- Non-GAAP adjusted net loss Q3 2026: $66.8M ($1.21/share) vs $37.2M ($0.78/share) in Q3 2025
- 78% of top 36 strategic accounts (~50% of addressable patients) have ordered REVTORPYK
- 91% of U.S. commercial and Medicare lives are in health plans that cover REVTORPYK
- Cash, cash equivalents and short-term investments: $642.7M at Sept 30, 2026; expected to fund operations through 2029
- sNDA submitted to FDA in Q3 2026 for PIK3CA mutant cohort based on positive Phase 3 VIKTORIA-1 data
- FDA approved REVTORPYK on July 14, 2026; NCCN gave preferred Category 1 recommendation on July 30, 2026
- Made $50M milestone payment to Pfizer triggered by FDA approval
Financial Impact
No product revenue in Q3; net loss $73.3M vs $43.8M YoY; cash burn $66.2M operating cash flow; $642.7M cash runway through 2029
Risk Factors
- No product revenue yet; launch revenue trajectory uncertain
- Operating expenses surged 81% YoY to $77.3M as commercial infrastructure builds out
- Stockholders' equity turned negative ($74M deficit) due to accumulated losses and convertible note accounting
- sNDA for PIK3CA mutant cohort under FDA review; approval not guaranteed
- Dependence on single product REVTORPYK for near-term revenue
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-449757 |
| Document: celc-20261105.htm | 0001193125-26-449757 |
| Document: 0001193125-26-449757-index-headers.html | 0001193125-26-449757 |
| Document: 0001193125-26-449757-index.html | 0001193125-26-449757 |
| Document: 0001193125-26-449757.txt | 0001193125-26-449757 |
| 8-K Data (Synthetic) | 0001193125-26-449757 |
Track record
26 reports on CELC
7 of 13 bullish or bearish reports moved the stock their way by T+5. Best: +26.84% at T+20 after the Jun 11, 2026 report. 9 of 13 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $62.58 Now $60.57 −3.21% settles Nov 23
- Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $64.37 Now $60.57 −5.90% settles Nov 23
- Nov 9, 20267d ago Press Release Bullish 5/10 Entry $70.37 to $60.57 Now $60.57 −13.93% ▼ −13.93% −12.23% vs SPY
- Nov 5, 202611d ago 8-K Neutral 5/10 Viewing No price data
- Nov 5, 202611d ago Press Release Neutral 5/10 Entry $66.79 to $64.37 Now $60.57 −9.31% ▼ −3.62% −6.22% vs SPY
- Nov 2, 202614d ago Institutional Cluster Neutral 3/10 Entry $69.72 to $67.05 Now $60.57 −13.12% ▼ −3.83% −3.24% vs SPY
- Oct 24, 202623d ago Press Release Bullish 6/10 Entry $65.80 to $69.13 Now $60.57 −7.95% ▲ +5.06% +6.32% vs SPY
- Oct 5, 20266w ago 3 Neutral 2/10 Entry $71.25 to $63.19 Now $60.57 −14.99% ▼ −11.31% −11.17% vs SPY
- Oct 2, 20266w ago 8-K Neutral 2/10 Entry $72.10 to $67.94 Now $60.57 −15.99% ▼ −5.77% −6.93% vs SPY
- Sep 30, 20266w ago 8-K Bullish 6/10 Entry $79.52 to $65.78 Now $60.57 −23.83% ▼ −17.28% −19.19% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers